Neil H Segal

15PUBLICATIONS
140CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Feb 26, 2026
Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma.

Paul B Romesser, Aron Bercz, Janet Alvarez

|Oct 30, 2025
Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.

Celine Yeh, Oliver Artz, Haochen Zhang

|Jan 14, 2025
Correlation Between Grade of Clinical Response to Neoadjuvant Therapy for Rectal Cancer and Oncologic Outcomes in the Era of Watch-and-Wait.

Roni Y Rosen, Aron P Bercz, Dana M Omer

|Aug 09, 2024
Clinical Calculator for Predicting Freedom From Recurrence After Resection of Stage I-III Colon Cancer in Patients With Microsatellite Instability.

Ayyuce Begum Bektas, Lynn Hakki, Asama Khan

|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.

Neil H Segal, Ignacio Melero, Victor Moreno

|Oct 26, 2023
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.

Floris S Verheij, Dana M Omer, Hannah Williams

Pageof 3

Frequent Collaborators

8 joint publications

Leonard Saltz

7 joint publications

Andrea Cercek

7 joint publications

Rona Yaeger

6 joint publications

Philip Paty